Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 345-354

  Triozzi, Pierre L ^a   Aldrich, Wayne ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

B16 melanoma; Docetaxel; Macrophages; Myeloid derived suppressor cells; Regulatory T cells; Temozolomide

Indexed keywords

DOCETAXEL; HUMAN RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MELANOMA B16; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TISSUE PRESSURE; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRHEUMATIC AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; DACARBAZINE; DRUG THERAPY, COMBINATION; EXTRACELLULAR FLUID; FEMALE; FLOW CYTOMETRY; IMMUNOENZYME TECHNIQUES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 77950538831     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y and Voronov E: The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25: 387-408, 2006.
2. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G and Herlyn M: Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56: 853-857, 1994.
3. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA and Apte RN: IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100: 2645-2650, 2003.
4. McKenzie RC, Oran A, Dinarello CA and Sauder DN: Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo. Anticancer Res 16: 437-441, 1996.
5. Lavi G, Voronov E, Dinarello CA, Apte RN and Cohen S: Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J Control Release 123: 123-130, 2007.
6. Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM and Alexander HR: The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 12: 1088-1096, 2006.
7. Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA and Aizawa H: Role of proinflammatory cytokine IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol 41: 661-670, 2009.
8. Ledeboer A, Jekich BM, Sloane EM, Mahoney JH, Langer SJ, Milligan ED, Martin D, Maier SF, Johnson KW, Leinwand LA, Chavez RA and Watkins LR: Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun 21: 686-698, 2007.
9. Twining CM, Sloane EM, Milligan ED, Chacur M, Martin D, Poole S, Marsh H, Maier SF and Watkins LR: Peri-sciatic proinflammatory cytokines, reactive oxygen species, and complement induce mirror-image neuropathic pain in rats. Pain 110: 299-309, 2004.
10. Surguladze D, Deevi D, Claros N, Corcoran E, Wang S, Plym MJ, Wu Y, Doody J, Mauro DJ, Witte L, Busam KJ, Pytowski B, Rodeck U and Tonra JR: Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res 69: 5643-5647, 2009.
11. Chang MJ, Yu WD, Reyno LM, Modzelewski RA, Egorin MJ, Erkmen K, Vlock DR, Furmanski P and Johnson CS: Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res 54: 5380-5386, 1994.
12. Wang Z, Lee KB, Reed E and Sinha BK: Sensitization by interleukin-1 alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo. Int J Cancer 68: 583-587, 1996.
13. Johnson CS: Interleukin-1: therapeutic potential for solid tumors. Cancer Invest 11: 600-608, 1993.
14. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, Voronov E and Apte RN: CD11b+/Gr-1+ immature myeloid cells mediate suppression of T-cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 175: 8200-8208, 2005.
15. Bunt SK, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S: Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 176: 284-290, 2006.
16. + effector T-cells. J Immunol 176: 7278-7287, 2006.
17. Bernengo MG, Quaglino P, Cappello N, Lisa F, Osella-Abate S and Fierro MT: Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients. Melanoma Res 10: 55-65, 2000.
18. Neville ME and Pezzella KM: Anti-tumour effects of interleukin 1 beta: in vivo induction of immunity to B16 melanoma, a non-immunogenic tumour. Cytokine 6: 310-317, 1994.
19. Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E, Kalofonos Ch, Skarlos D, Karabelis A and Kosmidis P: Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 20: 420-425, 2002.
20. Bronte V and Zanovello P: Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654, 2005.
21. Mills CD, Shearer J, Evans R and Caldwell MD: Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol 149: 2709-2714, 1992.
22. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T and Takami T: Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-and M2-type characteristics. J Leukoc Biol 83: 1136-1144, 2008.
23. Fontenot JD and Rudensky AY: A well-adapted regulatory contrivance: regulatory T-cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6: 331-337, 2005.
24. Triozzi PL, Aldrich W, Allen KO, Lima J, Shaw DR and Strong TV: Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of c-stimulatory molecules and granulocyte/macrophage colony-stimulating factor in mesothelioma. Int J Cancer 113: 406-414, 2005.
25. Wiig H, Tveit E, Hultborn R, Reed RK and Weiss L: Interstitial fluid pressure in DMBA-induced rat mammary tumors. Scand J Clin Lab Invest 42: 159-164, 1982.
26. Chou T-C and Talalay P: Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450-454, 1983.
27. Inoue K, Masuko-Hongo K, Okamoto M and Nishioka K: Efficacy of daily compared to intermittent administration of IL-1Ra for protection against bone and cartilage destruction in collagen-challenged mice. Clin Exp Rheumatol 21: 33-39, 2003.
28. Vidal-Vanaclocha F, Amézaga C, Asumendi A, Kaplanski G and Dinarello CA: Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res 54: 2667-2672, 1994.
29. Salnikov AV, Roswall P, Sundberg C, Gardner H, Heldin NE and Rubin K: Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 85: 512-521, 2005.
30. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L and Gajewski TF: Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 14: 3156-3167, 2008.
31. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H and Yu H: Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118: 3367-3377, 2008.
32. Tentori L, Leonetti C, Scarsella M, Muzi A, Vergati M, Forini O, Lacal PM, Ruffini F, Gold B, Li W, Zhang J, and Graziani G: Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur J Cancer 41: 2948-2957, 2005.
33. Bissery MC, Guénard D, Guéritte-Voegelein F and Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991
34. Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD and Krieg AM: Paclitaxel reduces regulatory T-cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 58: 615-628, 2009.
35. Jordan JT, Sun WH, Hussain SF, DeAngulo G, Prabhu SS and Heimberger AB: Preferential migration of regulatory T-cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57: 123-131, 2008.
36. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, Yeh NT, Mukaida N and Van Waes C: IL (interleukin)-1 promotes nuclear factor-B and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7: 1812-1820, 2001.
37. La E, Rundhaug JE, and Fischer SM: Role of intracellular interleukin-1 receptor antagonist in skin carcinogenesis. Mol Carcinog 30: 218-223, 2001.
38. Hsieh TC and Chiao JW: Growth modulation of human prostatic cancer cells by interleukin-1 and interleukin-1 receptor antagonist. Cancer Lett 95: 119-123, 1995.
39. Yamada Y, Karasaki H, Matsushima K, Lee GH and Ogawa K: Expression of an IL-1 receptor antagonist during mouse hepatocarcinogenesis demonstrated by differential display analysis. Lab Invest 79: 1059-1067, 1999.
40. Oelmann E, Kraemer A, Serve H, Reufi B, Oberberg D, Patt S, Herbst H, Stein H, Thiel E and Berdel WE: Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. Int J Cancer 71: 1066-1076, 1997.
41. Bunt SK, Yang L, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S: Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67: 10019-10026, 2007.
42. Sinha P, Clements VK and Ostrand-Rosenberg S: Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174: 636-645, 2005.
43. + immature myeloid suppressor cells mediate the development of tumor-induced T-regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131, 2006.
44. Benchekroun MN, Parker R, Dabholkar M, Reed E and Sinha BK: Effects of interleukin-1 alpha on DNA repair in human ovarian carcinoma (NIH:OVCAR-3) cells: implications in the mechanism of sensitization of cis- diamminedichloroplatinum(II). Mol Pharmacol 47: 1255-1260, 1995.
45. Braunschweiger PG, Basrur VS, Cameron D, Sharpe L, Santos O, Perras JP, Sevin BU and Markoe AM: Modulation of cisplatin cytotoxicity by interleukin-1 alpha and resident tumor macrophages. Biotherapy 10: 129-137, 1997.
46. Braunschweiger PG, Basrur VS, Santos O, Markoe AM, Houdek PV and Schwade JG: Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors. Cancer Res 53: 1091-1097, 1993.
47. Kubo H, Matsumoto K, Funahashi M, Takagi H, Kitajima Y, Taniguchi S and Saida T: Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice. Melanoma Res 10: 223-229, 2000.
48. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D and Nadler LM: Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11: 4430-4436, 2005.
49. Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P and Perrone F: Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6: 669-677, 2005.
50. + myeloid cells. Nat Biotechnol 25: 911-920, 2007.
51. Sica A and Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166, 2007.
52. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A and Sica A: A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation). Blood 107: 2112-2122, 2006.
53. Fitzpatrick FA and Wheeler R: The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 3: 1699-1714, 2003.
54. Konishi N, Miki C, Yoshida T, Tanaka K, Toiyama Y and Kusunoki M: Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma. Oncology 68: 138-145, 2005.
55. Kamimura D, Sawa Y, Sato M, Agung E, Hirano T and Murakami M: IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol 177: 306-314, 2006.
56. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S and Kuwano M: Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer 85: 182-188, 2000.
57. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G and Rivoltini L: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25: 2546-2553, 2007.
58. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E and Lokshin AE: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13: 2422-2428, 2007.